The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Open accessAbstract
PURPOSE: Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor–positive breast cancer has not been confirmed. PATIENTS AND METHODS: In the prospective, randomized, phase III PALLAS trial, patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer were randomly assigned to receive 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28-day cycle) with adjuvant endocrine therapy or adjuvant endocrine therapy alone (for at least 5 years). The primary end point of the study was invasive disease-free survival (iDFS); secondary end points were invasive breast cancer–free survival, distant recurrence-free survival, locoregional cancer-free survival, and overall survival. RESULTS: Among 5,796 patients enrolled at 406 centers in 21 countries worldwide over 3 years, 5,761 were included in the intention-to-treat population. At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (9.1%) patients who received endocrine therapy alone, with similar results between the two treatment groups (iDFS at 4 years: 84.2% v 84.5%; hazard ratio, 0.96; CI, 0.81 to 1.14; P = .65). No significant differences were observed for secondary time-to-event end points, and subgroup analyses did not show any differences by subgroup. There were no new safety signals for palbociclib in this trial. CONCLUSION: At this final analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor–positive breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“consistent differences in outcomes (OS and IDFS) have emerged across phase III studies of these therapies”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [22]
In the citing paper
“which in contrast to abemaciclib and ribociclib, has not shown a clinically meaningful or statistically significant difference in OS in the firstor second-line ABC setting or an invasive disease-free survival (IDFS) benefit in the EBC setting.17,18,21,22”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [22]
Citations
Cites
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationHarbeck, N., & Gnant, M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,387
Self-citationRibociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martín, M., Shao, Z. M., Zhang, Q. Y., Rodriguez, J. L. M., Campone, M., Hamilton, E. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02514 · Cited by 1,056
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Self-citation
Cited by
Sorted by citations
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L., Ding, Y., Chen, Y., Cai, Y., Wang, L., Huang, L., Liu, C., Shao, Z., & Yu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 1,170
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V. G., Aft, R., Agnese, D. M., Allison, K. H., Anderson, B. M., Bailey, J. E., Burstein, H. J., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0035 · Cited by 721
Self-citationRibociclib plus Endocrine Therapy in Early Breast Cancer
Slamon, D. J., Lipatov, O. N., Nowecki, Z. I., McAndrew, N. P., Kukiełka-Budny, B., Stroyakovskiy, D., Yardley, D. A., Huang, C., Fasching, P. A., Crown, J. P., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305488 · Cited by 440
Self-citationRecent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 351
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 381
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Morrison, L., Loibl, S., & Turner, N. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00840-4 · Cited by 290
Goetz, M. P., Toi, M., Huober, J., Sohn, J., Trédan, O., Park, I. H., Campone, M., Chen, S.-C., Manso, L. M., Paluch-Shimon, S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.013 · Cited by 238
Rastogi, P., O’Shaughnessy, J., Martín, M., Boyle, F. M., Cortés, J., Rugo, H. S., Goetz, M. P., Hamilton, E. P., Huang, C., Senkus, E., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01994 · Cited by 232
Self-citationSystemic therapy for early-stage breast cancer: learning from the past to build the future
Agostinetto, E., Gligorov, J., & Piccart, M. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00687-1 · Cited by 144
Hortobágyi, G. N., Łacko, A., Sohn, J., Cruz, F. M., Borrego, M. R., Manikhas, A., Park, Y. H., Stroyakovskiy, D., Yardley, D. A., Huang, C.-S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.10.015 · Cited by 133
Self-citationSlamon, D. J., Fasching, P. A., Hurvitz, S. A., Chia, S., Crown, J. P., Martín, M., Barrios, C. H., Bardia, A., Im, S., Yardley, D. A., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231178125 · Cited by 110
Kalinsky, K. M., Bianchini, G., Hamilton, E. P., Graff, S. L., Park, K. H., Jeselsohn, R. M., Demırcı, U., Martín, M., Layman, R. M., Hurvitz, S. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-02086 · Cited by 108
Ditsch, N., Wöcke, A., Untch, M., Jackisch, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., et al. (2022) · Breast Care · doi:10.1159/000524879 · Cited by 89
Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01701-9 · Cited by 83
“…phase III CDK4/6i trials in early breast cancer (no significant benefit for palbociclib [PALLAS, PENELOPE-B]; significant benefit for ribociclib [NATALEE], abemaciclib [MonarchE]) further suggest that results observed for palbociclib may not be relevant for the other approved CDK4/6is [21–26].”
BackgroundBalić, M., Thomssen, C., Gnant, M., & Harbeck, N. (2023) · Breast Care · doi:10.1159/000530584 · Cited by 68
Self-citationTargeting CDK4/6 in breast cancer
Shanabag, A., Armand, J., Son, E., & Yang, H. W. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01395-3 · Cited by 74
Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer
Pistilli, B., Lohrisch, C. A., Sheade, J. B., & Fleming, G. F. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_350358 · Cited by 64
Abdelmalak, M., Singh, R., Anwer, M. I., Ivanchenko, P., Randhawa, A., Ahmed, M., Ashton, A. W., Du, Y., Jiao, X., & Pestell, R. G. (2022) · Cancers · doi:10.3390/cancers14215388 · Cited by 45
Lauro, V. D., Barchiesi, G., Martorana, F., Zucchini, G., Muratore, M., Fontanella, C., Arpino, G., Mastro, L. D., Giuliano, M., Puglisi, F., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100629 · Cited by 44
Pfeiler, G., Hlauschek, D., Mayer, E. L., Deutschmann, C., Kacerovsky-Strobl, S., Martín, M., Meisel, J. L., Zdenkowski, N., Loibl, S., Balić, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00126 · Cited by 37
Self-citationRibociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer
Fasching, P. A., Stroyakovskiy, D., Yardley, D. A., Huang, C., Crown, J. P., Bardia, A., Chia, S., Im, S., Martín, M., Xu, B., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.3700 · Cited by 38
Kim, C., Lelond, S., Daeninck, P. J., Rabbani, R., Lix, L. M., McClement, S., Chochinov, H. M., & Goldenberg, B. A. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07709-3 · Cited by 33
Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer
Ring, A., Spataro, M., WICKI, A. N., & Aceto, N. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.929893 · Cited by 34
Chatterji, S., Krzoska, E., Thoroughgood, C. W., Saganty, J., Liu, P., Elsberger, B., Eid, R. A., & Speirs, V. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00633-7 · Cited by 32
Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion
Velez, B. C., Petrella, C., DiSalvo, K. H., Cheng, K., Kravtsov, R. L., Krasniqi, D., & Krucher, N. A. (2022) · Oncology Reports · doi:10.3892/or.2022.8469 · Cited by 31
Molecular mechanisms of cisplatin resistance in ovarian cancer
Jiang, C., Shen, C., Ni, M., Huang, L., Hu, H., Dai, Q. Y., Zhao, H., & Zhu, Z. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.032 · Cited by 33
Denkert, C., Rachakonda, S., Karn, T., Weber, K. E., Martin, M., Marmé, F., Untch, M., Bonnefoi, H. R., Kim, S., Seiler, S., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.002 · Cited by 31
Self-citationNabieva, N., & Fasching, P. A. (2023) · Cancers · doi:10.3390/cancers15061763 · Cited by 29
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
Johnston, S. R. D., Emde, A., Barrios, C. H., Srock, S., Neven, P., Martin, M., Cameron, D., Janni, W., & Gnant, M. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad045 · Cited by 30
Self-citationDong, M., Shan, B., Han, X., Zhao, X., Wang, F., Zhu, L., Ou, Q., Ma, X., & Pan, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.784985 · Cited by 25
Meirson, T., Goldstein, D. A., Gyawali, B., & Tannock, I. F. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00165-1 · Cited by 24
Antonarelli, G., Salimbeni, B. T., Marra, A., Espósito, A., Locatelli, M., Trapani, D., Pescia, C., Fusco, N., Curigliano, G., & Criscitiello, C. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104148 · Cited by 26
Pu, D., Xu, D., Wu, Y., Chen, H., Shi, G., Feng, D., Zhang, M., Liu, Z., & Li, J. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05516-1 · Cited by 25
CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
Haslam, A., Ranganathan, S., Prasad, V., & Olivier, T. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114192 · Cited by 25
Loibl, S., Martín, M., Bonnefoi, H. R., Untch, M., Kim, S., Bear, H. D., García-Sáenz, J. Á., Olivé, M. M., McCarthy, N. J., Gelmon, K. A., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.010 · Cited by 23
Self-citationExtended adjuvant endocrine therapy in early breast cancer: finding the individual balance
Lobo-Martins, S., Arecco, L., Pina-Cabral, T., Agostinetto, E., Dauccia, C., Franzoi, M. A., Mastro, L. D., Lambertini, M., Piccart, M. J., & de Azambuja, E. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105057 · Cited by 26
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 24
Fu, H., Wu, Z., Lei, Z., Teng, Q., Yang, Y., Ashby, C. R., Lei, Y., Lian, Y., & Chen, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.861642 · Cited by 23
Ragab, A., Raslan, R. R., Abusaif, M. S., Thabet, H. K., Ammar, Y. A., & Gohar, N. A. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117751 · Cited by 19
Dauccia, C., Agostinetto, E., Arecco, L., Lobo-Martins, S., Gitto, M., Lyon, A. R., López‐Fernández, T., Dent, S. F., Casalino, G., Agarwala, V., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105128 · Cited by 20
Emerging Targeted Therapies for Early Breast Cancer
Schlam, I. M., Tarantino, P., Morganti, S., Lynce, F. C., Trapani, D., Mayer, E. L., Garrido-Castro, A. C., Waks, A., & Tolaney, S. M. (2022) · Drugs · doi:10.1007/s40265-022-01781-5 · Cited by 19
Self-citationPei, J., Zhang, S., Yang, X., Han, C., Pan, Y., Li, J., Wang, Z., Sun, C., & Zhang, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101615 · Cited by 19
Curigliano, G., Dent, R. A., Llombart‐Cussac, A., Pegram, M. D., Pusztai, L., Turner, N. C., & Viale, G. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00560-z · Cited by 21
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
Klocker, E. V., Egle, D., Bartsch, R., Rinnerthaler, G., & Gnant, M. (2025) · Drugs · doi:10.1007/s40265-024-02144-y · Cited by 21
Self-citationCDK4/6 inhibitors: The Devil is in the Detail
Magge, T., Rajendran, S., Brufsky, A., & Foldi, J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01540-7 · Cited by 19
Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer
Hong, Y. C., He, J., Deng, D., Liu, Q., Zu, X., & Shen, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06367-9 · Cited by 20
Untch, M., Pérol, D., Mayer, E. L., Cortés, J., Nusch, A., Cameron, D., Barrios, C. H., Delea, T. E., Danyliv, A., Mishra, N., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113977 · Cited by 17
Self-citationCyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
Guo, Z., Dong, R. W., Wu, Y., Dong, S., & Alahari, S. K. (2025) · Oncogene · doi:10.1038/s41388-025-03378-0 · Cited by 18
Lee, S.-Y., Yoo, T.-K. R., Lee, S. B., Kim, J., Chung, I. Y., Ko, B. S., Kim, H. J., Lee, J. W., & Son, B. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-98176-9 · Cited by 15
Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer
Gnant, M., Turner, N. C., & Hernándo, C. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390922 · Cited by 17
Self-citationCDK4/6 as a Therapeutic Target in HR+/HER2− Breast Cancer Cells—Current Treatment Status
Krupa, K., Liszcz, A., Czerw, N., Czerw, A. I., Sygit, K., Kozłowski, R., Deptała, A., & Badowska-Kozakiewicz, A. M. (2025) · Cancers · doi:10.3390/cancers17061039 · Cited by 16
Tannock, I. F., Khan, Q. J., & Fojo, T. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02683 · Cited by 18
Strand, G. C., Johansson, N., Jakobsson, N., Bonander, C., & Svensson, M. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01285-4 · Cited by 14
Cardiotoxicity of Agents Used in Patients With Breast Cancer
Zagami, P., Trapani, D., Nicolò, E., Corti, C., Valenza, C., Criscitiello, C., Curigliano, G., & Carey, L. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00494 · Cited by 18
Wang, Y., Tsukamoto, Y., Hori, M., & Iha, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137156 · Cited by 14
Mayer, E. L., Hlauschek, D., Gnant, M., O’Brien, P., Bellet, M., Goetz, M. P., Ruíz-Borrego, M., Chan, A., Clifton, K., Egle, D., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.003 · Cited by 13
Self-citationAdjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
Agostinetto, E., Arecco, L., & de Azambuja, E. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00250-7 · Cited by 13
Ding, H., Xu, W., Dai, M., Li, S., Xin, W., Tong, Y., He, C., Mi, X., Zhan, Z., & Fang, L. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2348566 · Cited by 13
Tong, F., Lu, Y., Ma, H., & Shen, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31583 · Cited by 13
Marmé, F., Martin, M., Untch, M., Thode, C., Bonnefoi, H. R., Kim, S.-B., Bear, H. D., McCarthy, N. J., Gelmon, K. A., García-Sáenz, J. Á., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103466 · Cited by 13
Self-citationFasching, P. A., Slamon, D. J., Nowecki, Z. I., Kukiełka-Budny, B., Stroyakovskiy, D., Yardley, D. A., Huang, C., Chan, A., Chia, S., Martín, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1724 · Cited by 15
Self-citationPost-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
Agostinetto, E., Jacobs, F., Debien, V., Caluwé, A. D., Pop, C., Catteau, X., Aftimos, P. G., de Azambuja, E., & Buisseret, L. (2022) · Cancers · doi:10.3390/cancers14215467 · Cited by 14
Spring, L. M., Scarpetti, L., Medford, A. J., Niemierko, A., Comander, A. H., Mulvey, T. M., Schnipper, L. E., Isakoff, S. J., Moy, B., Wander, S. A., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-024-00708-5 · Cited by 13
The Role of CD4/6 Inhibitors in Breast Cancer Treatment
Purohit, L., Jones, C. X., Gonzalez, T., Castrellon, A. B., & Hussein, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021242 · Cited by 13
Nakamoto, S., Shien, T., Iwamoto, T., Kubo, S., Yamamoto, M., Yamashita, T., Kuwahara, C., & Ikeda, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-60101-x · Cited by 14
Talia, M., Cirillo, F., Scordamaglia, D., Dio, M. D., Zicarelli, A., Rosis, S. D., Miglietta, A., Capalbo, C., Francesco, E. M. D., Belfiore, A., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03096-7 · Cited by 14
Gentile, G., Scagnoli, S., Arecco, L., Santini, D., Botticelli, A., & Lambertini, M. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102769 · Cited by 12
Secreted LGALS3BP facilitates distant metastasis of breast cancer
Kim, S.-S., Park, I., Kim, J., Ka, N., Lim, G. Y., Park, M., Hwang, S., Kim, J.-E., Park, S. Y., Kim, J., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-024-01958-8 · Cited by 11
Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis
Papakonstantinou, A., Villacampa, G. J., Navarro, V., Oliveira, M., Valachis, A., Pascual, T., & Matikas, A. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103116 · Cited by 12
Brett, J. O., & Mayer, E. L. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01082-3 · Cited by 13
Self-citationInterstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer
Schlam, I. M., Giordano, A., & Tolaney, S. M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2288147 · Cited by 11
Cui, J., Sun, J., Zhou, X., Li, Y., Zhao, J., & Shen, G. (2024) · iScience · doi:10.1016/j.isci.2024.111370 · Cited by 10
Hussain, M., Brezden‐Masley, C., Chia, S., Curigliano, G., Webster, M. A., & Henning, J. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251326710 · Cited by 14
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty
Niraula, S. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102944 · Cited by 11
Ke, Y., Liao, C., Zhao, Z.-Q., Li, X., Lin, R., Yang, L., Zhang, H., & Kong, L.-M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880153 · Cited by 11
Bertucci, F., Finetti, P., Mamessier, É., & de Nonneville, A. T. (2023) · 癌症：英文版 · doi:10.1002/cac2.12466 · Cited by 10
Ergün, Y., Doğan, M., Uçar, G., Karaçin, P., & Karaçin, C. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2258791 · Cited by 10
de Moraes, F. C. A., Almeida, G. D. O., Alves, V. F. C., Priantti, J. N., Gomes, G. D. C., Carnevalli, S. V. B., Madeira, T., Vilbert, M., Stecca, C., Magalhães, M. C. F., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14050464 · Cited by 12
Nardin, S., Ruelle, T., Giannubilo, I., & Mastro, L. D. (2023) · Tumori Journal · doi:10.1177/03008916231216830 · Cited by 9
Tata Memorial Centre Evidence Based Management of Breast cancer
Wadasadawala, T., Joshi, S. P., Rath, S., Popat, P. B. T., Sahay, A., Gulia, S., BHARGAVA, P. G., Krishnamurthy, R., Hoysal, D. R., Shah, J., et al. (2024) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_55_24 · Cited by 10
Lorman-Carbó, N., Martínez‐Sáez, O., Fernández-Martínez, A., Galván, P., Chic, N., García-Fructuoso, I., Rodríguez, A., Gómez-Bravo, R., Schettini, F., Blasco, P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67126-2 · Cited by 10
O'Keefe, K., Desai, N. V., & Tan, A. R. (2024) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s271441 · Cited by 9
Novel targeted therapies and immunological strategies for breast cancer treatment
Mussa, A., Hamid, M. A. M., Talib, M., Ehinnou, I. B., Bragoli, A. J., Hajissa, K., Mokhtar, N. F., Mohamud, R., Al-Hatamleh, M. A. I., & Hassan, R. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117929 · Cited by 10
Abdel‐Razeq, H., & Sharaf, B. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s356757 · Cited by 9
Recommendations for the diagnosis and treatment of patients with early breast cancer: update 2023
Köpke, M. B., Aktas, B., & Ditsch, N. C. (2023) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000835 · Cited by 9
CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
Akhade, A., Wambeke, S. V., & Gyawali, B. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.ed124 · Cited by 9
Optimizing public-private partnerships to support clinical cancer research
Herbst, R. S., Blumenthal, G. M., Khleif, S. N., Lippman, S. M., Meropol, N. J., Rosati, K., Shulman, L. N., Smith, H., Wang, M., Winn, R. A., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae279 · Cited by 8
Salvage Therapy for Isolated Local-Regional Breast Cancer Recurrence
Choi, J. I., Rodin, D. L., Patel, R. D., Sparano, J. A., Khan, A. J., & Gerber, N. K. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.05.077 · Cited by 8
NF1-depleted ER + breast cancers are differentially sensitive to CDK4/6 inhibitors
Zheng, Z.-Y., Chen, A., Jaehnig, E. J., Anurag, M., Lei, J. T., Feng, L., Wang, C., Fandino, D. M., Singh, P., Kennedy, H., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq5492 · Cited by 9
Pandey, P., Sharma, A., & Gogia, A. (2023) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2023.100959 · Cited by 9
Hershman, D. L., Chen, B. E., Sathe, C. M., Parulekar, W. R., Lemieux, J., Ligibel, J. A., Gelmon, K. A., Whelan, T. J., & Goodwin, P. J. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06922-2 · Cited by 8
Beddok, A., Mouren, V., Cottu, P. H., Laki, F., Fourquet, A., & Kirova, Y. (2023) · International Journal of Cancer · doi:10.1002/ijc.34562 · Cited by 8
Giraudo, A., Sabatier, R., Rousseau, F., de Nonneville, A. T., Gonçalvès, A., Cécile, M., Braticevic, C., Viret, F., Seguin, L., Kfoury, M., et al. (2024) · Cancers · doi:10.3390/cancers16101838 · Cited by 9
Keskinkılıç, M., Arayıcı, M. E., Başbınar, Y., Ellıdokuz, H., Yavuzşen, T., & Öztop, İ. (2024) · The Breast · doi:10.1016/j.breast.2024.103815 · Cited by 9
Mata, D. G. D. M. M., Carmona, C. A., Eisen, A. F., & Trudeau, M. (2022) · Current Oncology · doi:10.3390/curroncol29070394 · Cited by 8
Agostinetto, E., Pfeiler, G., Hlauschek, D., Mayer, E. L., Lambertini, M., de Azambuja, E., Bellet, M., Meisel, J. L., Rubovszky, G., Zdenkowski, N., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104096 · Cited by 7
Self-citationAntioxidant Senotherapy by Natural Compounds: A Beneficial Partner in Cancer Treatment
Aleksandrova, Y. R., & Неганова, М. Е. (2025) · Antioxidants · doi:10.3390/antiox14020199 · Cited by 8
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
Knudsen, E. S., Witkiewicz, A. K., & Kabraji, S. K. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01431-5 · Cited by 8
Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending
Goldstein, D. A., Saltz, L. B., Pond, G. R., & Tannock, I. F. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000287 · Cited by 7
Oral Maintenance Therapy in Early Breast Cancer—How Many Patients Are Potential Candidates?
Tauber, N., Hilmer, L., Dannehl, D., Fick, F., HEMPTENMACHER, F. C., Krawczyk, N., Meyer-Lehnert, T., Milewski, K., Princk, H., Hartkopf, A. D., et al. (2025) · Cancers · doi:10.3390/cancers17010145 · Cited by 7
Metadata
- Authors
- Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., Pfeiler, G., Miller, K. D., Colleoni, M., Suga, J. M., Rubovsky, G., Bliss, J. M., Mayer, I. A., Singer, C. F., Nowecki, Z., Hahn, O., Thomson, J., Wolmark, N., Amillano, K., Rugo, H. S., Steger, G. G., Hernando Fernández de Aránguiz, B., Haddad, T. C., Perelló, A., Bellet, M., Fohler, H., Metzger Filho, O., Jallitsch-Halper, A., Solomon, K., Schurmans, C., Theall, K. P., Lu, D. R., Tenner, K., Fesl, C., DeMichele, A., Mayer, E. L., & on behalf of the PALLAS groups and investigators
- Affiliations
- Comprehensive Cancer Center Vienna (AT)
- Mayo Clinic (US)
- Austrian Breast & Colorectal Cancer Study Group (AT)
- Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Dana-Farber Cancer Institute (US)
- Paracelsus Medical University (AT)
- Government of New South Wales (AU)
- Johns Hopkins University (US)
- Curtin University (AU)
- Indiana University Health (US)
- European Institute of Oncology (IT)
- Kaiser Permanente Vallejo Medical Center (US)
- National Institute of Oncology, Budapest, Hungary
- Institute of Cancer Research (GB)
- Vanderbilt University Medical Center (US)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- University of Chicago (US)
- Peninsula Health (AU)
- University of Pittsburgh (US)
- Hospital Universitari Sant Joan de Reus (ES)
- University of California, San Francisco (US)
- GEICAM Spanish Breast Cancer Group, Madrid, Spain
- Hospital Universitario Son Espases (ES)
- Vall d'Hebron Institute of Oncology (ES)
- Alliance Foundation Trials (US)
- BIG, Brussels, Belgium
- Pfizer (United States) (US)
- University of Pennsylvania (US)
- GEICAM – Spanish Breast Cancer Group (ES)
- ORCID
- Gnant, Michael
- Dueck, Amylou C.
- Martin, Miguel
- Greil, Richard
- Fox, Peter
- Wolff, Antonio C.
- Chan, Arlene
- Winer, Eric P.
- Pfeiler, Georg
- Miller, Kathy D.
- Colleoni, Marco
- Suga, Jennifer M.
- Rubovsky, Gabor
- Bliss, Judith M.
- Mayer, Ingrid A.
- Singer, Christian F.
- Nowecki, Zbigniew
- Thomson, Jacqui
- Wolmark, Norman
- Amillano, Kepa
- Rugo, Hope S.
- Steger, Guenther G.
- Hernando Fernández de Aránguiz, Blanca
- Haddad, Tufia C.
- Perelló, Antonia
- Bellet, Meritxell
- Metzger Filho, Otto
- Schurmans, Céline
- Lu, Dongrui R.
- Tenner, Kathleen
- Fesl, Christian
- DeMichele, Angela
- Mayer, Erica L.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-01-20
- Volume
- 40
- Issue
- 3
- Pages
- 282-293
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC10476784
- OpenAlex
- W4200066800
- Cited by
- 235
- References
- 46
- Citations by year
- 2026: 26 · 2025: 70 · 2024: 56 · 2023: 51 · 2022: 32
- FWCI
- 22.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Pfizer
- Cancer Research UK (25351)
- National Institute for Health and Care Research (NIHR202432)
- National Cancer Institute (U10CA180868, R01CA214893)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, early breast cancer, hormone receptor-positive breast cancer, HER2-negative breast cancer, adjuvant therapy, endocrine therapy, invasive disease-free survival, PALLAS trial
- MeSH terms
- Progression-Free Survival, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Mastectomy, Middle Aged, Neoplasm Staging, Piperazines, Prospective Studies, Pyridines, Time Factors, Chemotherapy, Adjuvant, Disease Progression, Disease-Free Survival, Antineoplastic Agents, Hormonal, Neoadjuvant Therapy, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
